Based on previous findings, we hypothesized that Vasohibin 2 (VASH2) protein may induce epithelial-mesenchymal transition (EMT) of pancreatic cancer (PC) cells by promoting the malignant behaviors of these cells. The present study aimed to test this hypothesis and explore the possible mechanisms involved.

Methods

The expression of VASH2 in PC tissues and cell lines was detected by quantitative real-time PCR and Western blot. PC cells with overexpression or knockdown of VASH2 were used to examine the involvement of VASH2 in EMT by detecting the expression of epithelial (E-cadherin) and mesenchymal (vimentin) markers and EMT-related transcription factor ZEB1/2, in gemcitabine resistance and tumor cell invasion by apoptosis and invasion assays, and in cancer stem cell-like phenotypes by detecting the proportion of CD24⁺CD44⁺ and side population (SP) cells in PC cells with flow cytometry. The impact of VASH2 overexpression and knockdown on components of the Hedgehog signaling pathway was also assessed.

Results

We found that VASH2 was highly expressed in PC tissues and cells. It promoted the EMT of PC cells by altering ZEB1/2 expression. VASH2 also stimulated invasion and chemotherapeutic resistance of PC cells and increased the proportion of cancer stem-like cells in PC cells. VASH2 did so by upregulating the expression of multiple molecules in the Hedgehog signaling pathway of PC cells.

Conclusion

VASH2 promotes malignant behaviors of PC cells by inducing EMT via activation of the Hedgehog signaling pathway.

CONFLICT OF INTEREST

None declared.

REFERENCES

1Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1): 7-30.
10.3322/caac.21332
PubMed Web of Science® Google Scholar
2Feng HY, Chen YC. Role of bile acids in carcinogenesis of pancreatic cancer: an old topic with new perspective. World J Gastroenterol. 2016; 22(33): 7463-7477.
10.3748/wjg.v22.i33.7463
CAS PubMed Web of Science® Google Scholar
3Varghese AM, Lowery MA, Yu KH, et al. Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer. 2016; 122: 3765-3775.
10.1002/cncr.30342
PubMed Web of Science® Google Scholar
4Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 2003; 4(8): 657-665.
10.1038/nrm1175
CAS PubMed Web of Science® Google Scholar
5Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006; 7(2): 131-142.
10.1038/nrm1835
CAS PubMed Web of Science® Google Scholar
6Polireddy K, Chen Q. Cancer of the pancreas: molecular pathways and current advancement in treatment. J Cancer. 2016; 7(11): 1497-1514.
10.7150/jca.14922
CAS PubMed Web of Science® Google Scholar
7Hindriksen S, Bijlsma MF. Cancer stem cells, EMT, and developmental pathway activation in pancreatic tumors. Cancers (Basel). 2012; 4(4): 989-1035.
10.3390/cancers4040989
CAS PubMed Google Scholar
8Zhang Y, Wei J, Wang H, et al. Epithelial mesenchymal transition correlates with CD24+ CD44+ and CD133+ cells in pancreatic cancer. Oncol Rep. 2012; 27(5): 1599-1605.
CAS PubMed Web of Science® Google Scholar
9Shibuya T, Watanabe K, Yamashita H, et al. Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin. Arterioscler Thromb Vasc Biol. 2006; 26(5): 1051-1057.
10.1161/01.ATV.0000216747.66660.26
CAS PubMed Web of Science® Google Scholar
10Kimura H, Miyashita H, Suzuki Y, et al. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood. 2009; 113(19): 4810-4818.
10.1182/blood-2008-07-170316
CAS PubMed Web of Science® Google Scholar
11Xue X, Gao W, Sun B, et al. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene. 2013; 32(13): 1724-1734.
10.1038/onc.2012.177
CAS PubMed Web of Science® Google Scholar
12Norita R, Suzuki Y, Furutani Y, et al. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-beta signaling. Cancer Sci. 2017; 108(3): 419-426.
10.1111/cas.13157
CAS PubMed Web of Science® Google Scholar
13Tu M, Li H, Lv N, et al. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2. Mol Cancer. 2017; 16(1): 66.
10.1186/s12943-017-0619-6
PubMed Web of Science® Google Scholar
14Xue X, Zhang Y, Zhi Q, et al. MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumors by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. Cell Commun Signal. 2014; 12: 62.
10.1186/s12964-014-0062-x
PubMed Web of Science® Google Scholar
15Wang R, Cheng L, Xia J, et al. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1alpha in pancreatic cancer cells. Curr Cancer Drug Targets. 2014; 14(4): 407-417.
10.2174/1568009614666140226114015
PubMed Web of Science® Google Scholar
16Murase M, Kano M, Tsukahara T, et al. Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer. 2009; 101(8): 1425-1432.
10.1038/sj.bjc.6605330
CAS PubMed Web of Science® Google Scholar
17Wang F, Ma L, Zhang Z, et al. Hedgehog signaling regulates epithelial-mesenchymal transition in pancreatic cancer stem-like cells. J Cancer. 2016; 7(4): 408-417.
10.7150/jca.13305
CAS PubMed Web of Science® Google Scholar
18Tu M, Lu C, Lv N, et al. Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2. Cancer Lett. 2016; 383(2): 272-281.
10.1016/j.canlet.2016.09.031
CAS PubMed Web of Science® Google Scholar
19Borowa-Mazgaj B. Pancreatic cancer–mechanisms of chemoresistance][J. Postepy Hig Med Dosw (Online). 2016; 70: 169-179.
10.5604/17322693.1196387
PubMed Google Scholar
20Beuran M, Negoi I, Paun S, et al. The epithelial to mesenchymal transition in pancreatic cancer: a systematic review. Pancreatology. 2015; 15(3): 217-225.
10.1016/j.pan.2015.02.011
CAS PubMed Web of Science® Google Scholar
21Satoyoshi R, Kuriyama S, Aiba N, et al. Asporin activates coordinated invasion of scirrhous gastric cancer and cancer-associated fibroblasts. Oncogene. 2015; 34(5): 650-660.
10.1038/onc.2013.584
CAS PubMed Web of Science® Google Scholar
22Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule. Nat Rev Cancer. 2011; 11(4): 254-267.
10.1038/nrc3023
PubMed Web of Science® Google Scholar
23Wang L, Wu H, Wang L, et al. Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms. Cancer Lett. 2017; 398: 24-36.
10.1016/j.canlet.2017.04.001
CAS PubMed Web of Science® Google Scholar
24Li Y, Vandenboom TN, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009; 69(16): 6704-6712.
10.1158/0008-5472.CAN-09-1298
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume7, Issue11

November 2018

Pages 5567-5576

Vasohibin 2 promotes malignant behaviors of pancreatic cancer cells by inducing epithelial-mesenchymal transition via Hedgehog signaling pathway

Abstract

Background

Methods

Results

Conclusion

CONFLICT OF INTEREST

REFERENCES

Citing Literature

Figures

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Vasohibin 2 promotes malignant behaviors of pancreatic cancer cells by inducing epithelial-mesenchymal transition via Hedgehog signaling pathway

Abstract

Background

Methods

Results

Conclusion

CONFLICT OF INTEREST

REFERENCES

Citing Literature

Figures

References

Related

Information